Tomentosin shows anticancer effect on U87 human glioblastoma multiforme cells

Abstract

Glioblastoma multiforme (GBM) is one of the most common brain tumors. Chemotherapy, radiotherapy and surgical resection are methods used in GBM treatment, however, the investigation of possible anticancer effects of low-toxicity natural products on various cancer cells, including GBM, leads to promising results. In this study, it was aimed to investigate anticancer effect of tomentosin, which is a sesquiterpene lactone, on U87 human GBM cells. The cytotoxic effect of tomentosin was evaluated by XTT assay. The concentration of tomentosin that inhibits 50% cell viability (IC50) was determined by the results from XTT, and, in further analyzes cells were treated with tomentosin at IC50 concentration. Then, total RNA isolation and cDNA synthesis were performed in control and dose groups, and, the possible anticancer effect of tomentosin was determined by evaluating the expression levels of important genes associated with apoptosis and metastasis by qPCR analysis. In addition, the effect of tomentosin on the colony forming capacity of GBM cells was evaluated by colony formation assay. According to our results, IC50 dose of tomentosin was found to be 28.8 µM in U87 cells for 48 hours. When compared to the control group, tomentosin increased expression of BAX, CASP3, CASP8, CASP9, CYCS, FADD, TNF, TNFR1, TNFR2 and TIMP2 genes. And, tomantosin significantly decreased colony forming capacity of U87 cells. In conclusion, it is thought that tomentosin exerts its anticancer effect by changing the expression levels of genes associated with apoptosis and metastasis in U87 GBM cells.